bhc-20260519

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

MAY 19, 2026

Date of report (Date of earliest event reported)

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

Canada

001-14956

98-0448205

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, No Par Value	BHC	New York Stock Exchange	Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 19, 2026, Bausch Health Companies Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following three proposals, each of which is described in detail in the Company’s Management Proxy Circular and Proxy Statement. The results of each matter voted upon are as follows:

Proposal No. 1: Election of Directors. The shareholders elected the following individuals to the Company’s Board of Directors, including Eiry W. Roberts, M.D., who was elected as a new director, to serve until the close of the Company’s 2027 Annual Meeting of Shareholders, until their successors are duly elected or appointed, or until such director’s earlier resignation or removal:



Name	For	Withheld	Broker Non-Votes
Thomas J. Appio	196,814,621	2,743,810	79,859,606
Christian A. Garcia	196,711,908	2,846,523	79,859,606
Michael Goettler	196,757,828	2,800,603	79,859,606
Sarah B. Kavanagh	188,459,870	11,098,561	79,859,606
Frank D. Lee	183,885,617	15,672,814	79,859,606
Sandra Leung	195,931,772	3,626,659	79,859,606
John A. Paulson	196,214,806	3,343,625	79,859,606
Robert N. Power	186,236,066	13,322,365	79,859,606
Eiry W. Roberts, M.D.	196,972,752	2,585,679	79,859,606
Amy B. Wechsler, M.D.	195,813,955	3,744,476	79,859,606

Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement.



For	Against	Abstain	Broker Non-Votes
189,432,400	9,588,417	537,614	79,859,605

Proposal No. 3: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2027 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration.



For						Withheld
276,774,936						2,643,100

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 19, 2026


			BAUSCH HEALTH COMPANIES INC.


By:			/s/ Seana Carson
			Seana Carson
			Executive Vice President, General Counsel

Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders